Amarin Co. plc (NASDAQ:AMRN) – Equities research analysts at Jefferies Group reduced their FY2020 earnings per share estimates for shares of Amarin in a research report issued on Wednesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the year, down from their prior estimate of $0.06. Jefferies Group also issued estimates for Amarin’s FY2021 earnings at $0.12 EPS and FY2022 earnings at $0.33 EPS.
Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $53.87 million for the quarter, compared to the consensus estimate of $52.73 million. During the same quarter in the previous year, the company earned ($0.10) EPS. Amarin’s revenue was up 39.2% compared to the same quarter last year.
Shares of Amarin (NASDAQ:AMRN) traded down $0.09 on Thursday, reaching $3.47. 1,420,100 shares of the company were exchanged, compared to its average volume of 2,254,171. Amarin has a twelve month low of $2.85 and a twelve month high of $4.60. The firm has a market cap of $1,032.60, a price-to-earnings ratio of -13.48 and a beta of 0.50. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63.
In other Amarin news, insider Steven B. Ketchum sold 128,257 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $4.25, for a total transaction of $545,092.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Steven B. Ketchum sold 135,205 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $4.41, for a total transaction of $596,254.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 426,720 shares of company stock worth $1,814,296. 3.72% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. TD Asset Management Inc. acquired a new position in shares of Amarin during the 3rd quarter worth approximately $285,000. Alkeon Capital Management LLC acquired a new position in shares of Amarin during the 3rd quarter worth approximately $7,875,000. Neuberger Berman Group LLC acquired a new position in shares of Amarin during the 3rd quarter worth approximately $350,000. Alps Advisors Inc. acquired a new position in shares of Amarin during the 4th quarter worth approximately $1,203,000. Finally, Opaleye Management Inc. acquired a new position in shares of Amarin during the 4th quarter worth approximately $3,448,000. Hedge funds and other institutional investors own 37.28% of the company’s stock.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.